Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study

Panadol Osteo PBS Claims Cohort Study

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02262702

Enrollment

Registered

2014-10-13

Start date

2013-01-31

Completion date

2013-01-31

Last updated

2016-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

The aim of this observational study is to compare the use of an extended release paracetamol formulation with standard paracetamol in a cohort of Australian concessional patients with osteoarthritis (OA), to assess differences in prescribing patterns and patient compliance.

Detailed description

This retrospective analysis of physician prescribing data (long-term concessional cohort from the Medicare Australia PBS claims dataset for the time period 2008-2011 (4 years) will compare the use of extended release paracetamol (Panadol Osteo) with standard paracetamol 500mg in a cohort of Australian concessional patients with OA, to assess differences in prescribing patterns and patient compliance.

Interventions

DRUGParacetamol 665 mg

Paracetamol 665 mg tablet

DRUGParacetamol 500 mg

Paracetamol 500 mg tablet

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Participants prescribed with a paracetamol product and categorized as a concessional patient * Participants with new episodes of OA (no history of OA paracetamol in previous 12 months) or suffering from chronic OA (history of OA paracetamol in the previous 12 months)

Exclusion criteria

* Participants with Rheumatoid arthritis or other auto-immune inflammatory conditions * Participants receiving the following anti-rheumatoid therapies:Immunimodulators such as methotrexate, leflunamide and TNF blockers * Participants receiving treatment for cancer pain

Design outcomes

Primary

Measure	Time frame	Description
Relative number of prescriptions of an extended release paracetamol formulation and a standard release paracetamol formulation.	January 2009 to December 2010	Number of episodes of treatment for OA with the extended release formulation and the standard release formulatins will be counted.
Relative treatment compliance with an extended release paracetamol formulation and a standard release paracetamol formulation	January 2009 to December 2010	Interval between the repeat doses of extended release paracetamol formulation and the standard release paracetamol formulation.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026